Read more
Transporters in Drug Discovery and Development: Detailed Concepts and Best Practice, 2nd Edition is a comprehensive book providing a detailed overview of significant drug transporter families, their roles in disease causation due to functional defects, and their importance in drug discovery and development. Building upon the foundation set by the first edition, this updated version covers various topics, including clinically relevant drug transporter-related pharmacokinetics variations, drug-drug interactions (DDIs), genetic polymorphisms, transporter-related organ toxicity, and methodologies for studying drug transporters. It also highlights the translational aspect in drug discovery and development. The revision explores the advancements in transporter research, such as the emerging use of transporters as pharmacological targets, the evolving application of modeling and simulation, and the innovative use of endogenous biomarkers in assessing transporter activities during drug clinical trials.
Transporters in Drug Discovery and Development: Detailed Concepts and Best Practice, 2nd Edition provides a deeper understanding of transporter research and its implications. It is an invaluable resource for researchers, students, and professionals in the field, offering insights that could potentially revolutionize drug discovery and development.
List of contents
1. Membrane transporters and the diseases corresponding to functional defects
2. P-glycoprotein (P-gp/MDR1)/ABCB1
3. Multidrug resistance-associated protein 2 (MRP2/ABCC2)
4. Breast cancer resistance protein (BCRP)/ABCG2
5. The bile salt hemostasis transporters: BSEP/ABCB11, NTCP, OSTa/b, ASBT and MDR3
6. Organic anion- transporting polypeptides (OATPs/SLCOs)
7. Organic anion, organic cation, and zwitterion transporters of the SLC22 and SLC47 superfamily (OATs, OCTs, OCTNs, and MATEs)
8. Drug transporters in drug discovery and development.
9. Transporter study methodologies.
10. Transporters as pharmacological targets
11. Transporter endogenous substrates as biomarkers for transporter activities
12. Pharmacokinetics model analysis for transporter-mediated drug disposition and clearance.
About the author
Yurong Lai is a senior principal scientist at a US-based pharmaceutical company. He received his M.D. from Fujian Medical University in China and a Ph.D. (Toxicology) from Sapporo Medical University in Japan. From 1998 to 2001, he was a research fellow of Japanese Society for Promotion (JSPS) in Department of Physiopathology, Graduate School of Medicine of Hokkaido University, followed by a position as Research Associate in Department of Pharmaceutics, University of Washington
